METHOD ARTICLE

Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry [version 3; peer review: 2 approved]

Adeniyi Olagunju1,2, Jacinta Nwogu3, Oluwasegun Eniayewu2,4, Shakir Atoyebi1,2, Aliu Amara1, John Kpamor5, Oluseye Bolaji2, Ebunoluwa Adejuyigbe6, Andrew Owen1, Saye Khoo1

1Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
2Department of Pharmaceutical Chemistry, Obafemi Awolowo University, Ile-Ife, Nigeria
3Department of Pharmaceutical Chemistry, University of Ibadan, Ibadan, Nigeria
4Department of Pharmaceutical and Medicinal Chemistry, University of Ilorin, Ilorin, Nigeria
5Federal Medical Centre, Makurdi, Nigeria
6Department of Paediatrics and Child Health, Obafemi Awolowo University, Ile-Ife, Nigeria

Abstract

Background: A liquid chromatography tandem mass spectrometry method to quantify drugs in dried cervicovaginal secretions from flocked swabs was developed and validated using the antiretroviral efavirenz as an example.

Methods: Cervicovaginal swabs (CVS) were prepared by submerging flocked swabs in efavirenz-spiked plasma matrix. Time to full saturation, weight uniformity, recovery and room temperature stability were evaluated. Chromatographic separation was on a reverse-phase C18 column by gradient elution using 1mM ammonium acetate in water/acetonitrile at 400 µL/min. Detection and quantification were on a TSQ Quantum Access triple quadrupole mass spectrometer operated in negative ionisation mode. The method was used to quantify efavirenz in CVS samples from human immunodeficiency virus (HIV)-positive women in the VADICT study (NCT03284645). A total of 98 samples (35 paired intensive CVS and DBS pharmacokinetic samples, 14 paired sparse CVS and DBS samples) from 19 participants were available for this analysis.

Results: Swabs were fully saturated within 15 seconds, absorbing 128 µL of plasma matrix with coefficient of variation (%CV) below 1.3%. The method was linear with a weighting factor (1/X) in the range of 25-
10000 ng/mL with inter- and intra-day precision (% CV) of 7.69-14.9%, and accuracy (% bias) of 99.1-105.3%. Mean recovery of efavirenz from CVS was 83.8% (%CV, 11.2) with no significant matrix effect. Efavirenz remained stable in swabs for at least 35 days after drying and storage at room temperature. Median (range) CVS efavirenz AUC \(0-24\) was 16370 ng*h/mL (5803-22088), \(C_{\text{max}}\) was 1618 ng/mL (610-2438) at a \(T_{\text{max}}\) of 8.0 h (8.0-12), and \(C_{\text{min}}\) was 399 ng/mL (110-981). Efavirenz CVS:plasma AUC \(0-24\) ratio was 0.41 (0.20-0.59).

**Conclusions**: Further application of this method will improve our understanding of the pharmacology of other therapeutics in the female genital tract, including in low- and middle-income countries.

**Keywords**
LC-MS/MS, Cervicovaginal fluid, Swab, Pharmacokinetics, Efavirenz
**Introduction**

Heterosexual transmission through the genital mucosa and mother-to-child transmission, mainly during delivery, are major routes of human immunodeficiency virus (HIV) acquisition in Sub-Saharan Africa. High HIV ribonucleic acid (RNA) in genital secretions is a known risk factor for sexual transmission, independent of plasma HIV concentration\(^1\). HIV shedding in the female genital tract has been shown to increase the risk of mother-to-child transmission during delivery\(^2\). Therefore, adequate penetration of antiretroviral (ARV) drugs into this compartment to achieve undetectable HIV RNA is critical to minimize the risk of transmission\(^3\). For instance, differential accumulation of tenofovir and emtricitabine in rectal fluid versus female genital secretions has been observed\(^4\), an observation consistent with differential expression of efflux transporters\(^5\). A proper understanding of ARV pharmacokinetics in the female genital tract is crucial in developing effective pre-exposure prophylaxis (PrEP) and prevention of mother-to-child transmission interventions.

Cervicovaginal fluid concentration has been shown to be an acceptable surrogate for tissue concentration\(^6\). However, developing and validating a method to quantify drugs in the female genital tract is challenging and several methods have been reported, including the use of menstrual cup and cervicovaginal lavage. Limited sample volumes and difficulty in standardizing dilution practices are major limitations associated with these methods. The use of cervicovaginal cotton-based smears and swabs have also been explored, suboptimal analyte extraction being a major drawback. Polyester-based materials offer better analyte recovery than cotton-based materials. For instance, Bennetto-Hood et al. described an ophthalmic tear strip wicking method in which standards and quality control samples were prepared by applying 7 µL of spiked blank cervicovaginal fluid\(^7\). In many of these methods, the applied volumes differ from the capacity of the collection devices. In a method where the applied volumes (25 µL on ophthalmic tear strips, 125 µL on polyester-based swabs) fully saturated the devices, preparation of standards and quality control samples did not replicate real-life sample collection. Hence in both scenarios, clinical application of these methods will require weighing the devices pre- and post-collection to allow for normalization of fluid collected.

More recently, flocked swabs with perpendicular nylon fibers on the tip of a solid molded plastic applicator shaft have become available. In this paper, we report the validation and clinical application of a liquid chromatography tandem mass spectrometry method for efavirenz quantification in flocked cervicovaginal swabs (CVS) that accurately mimics real life specimen collection process. Importantly, we extended the application of this method to settings with inadequate ultra-low temperature storage facilities by validating room temperature drying and storage.

**Methods**

**Materials**

Reference standards of efavirenz (E425000) and \(^{13}\)C-labelled efavirenz (E425001), used as internal standard, were obtained from Toronto Research Chemicals Inc. (North York, ON, Canada). LC-MS grade acetonitrile (106166S3) was obtained from Fisher Scientific (Loughborough, Leicestershire, UK), methanol (83638.320P) from VWR International (Lutterworth, Leicestershire, UK), and formic acid from Sigma-Aldrich (Gillingham, Dorset, UK). Water was produced from an Elga Option-S water purification unit (Elga Labwater, High Wycombe, Buckinghamshire, UK) and further purified to 18.2 MQ with the Purelab Ultra (Elga LabWater, High Wycombe, Buckinghamshire, UK). FLOQSwabs® (520CS01) were obtained from COPAN Diagnostics Inc. (Murrieta, CA, USA). Dried blood spots cards (Whatman 903 Protein Saver) were purchased from GE Healthcare Life Sciences (New York, NY, USA). Blank plasma was obtained from drug-free healthy volunteers.

**Liquid chromatography tandem mass spectrometry system and conditions**

The liquid chromatography tandem mass spectrometry system and conditions were as previously described for the quantification of efavirenz in dried blood spot\(^7\) and dried breastmilk spot\(^8\). In brief, chromatographic separation was on a reverse phase Fortis™ C18 column 3 µm, 10cm x 2.1 mm (Fortis Technologies Ltd, Neston, Cheshire, UK) with a 2 µm C18 Quest column-saver (Thermo Electron Corporation, Hemel Hempstead, Hertfordshire, UK). The mobile phase consisted of 1mM ammonium acetate in 30:70 acetonitrile: water (mobile phase A) and 1mM ammonium acetate in acetonitrile (mobile phase B) in gradient elution at a flow rate of 400µL/min over 7 minutes. The total injection volume was 10 µL and 3 mL MeOH-water (1:1, v/v) was used as wash solvent between injections. Detection was on the TSQ Quantum Access (Thermo Electron Corporation, Hemel Hempstead, Hertfordshire, UK) with a heated electrospray ionisation source operated in the negative ionisation mode and selective reaction monitoring. Xcalibur™ was used for compound tuning and optimisation while the LCQuan™ (version 2.7.0, Thermo Fisher Scientific, Hemel Hempstead, UK) was used for sequence acquisition and processing.

**Swab saturation and weight uniformity**

The weight uniformity of the swabs was evaluated by individually weighing 20 blank swabs. The percentage deviation from the mean weight was computed in each case. Time to complete saturation was assessed by inserting the previously weighed...
swabs in plasma for different lengths of time from 5 to 120 sec and 12 h (n = 10 per duration). The weight uniformity of completely saturated swabs was assessed.

Preparation of stock solutions, plasma calibration standards (STD) and quality controls (QC) samples
Efavirenz and 13C-labeled efavirenz stock solutions were prepared from their respective reference standards in methanol to obtain a final concentration of 1 mg/mL and stored at -20 °C until use. Working stock of efavirenz in plasma were prepared by spiking an appropriate volume of the 1 mg/mL stock solution into blank plasma to obtain final concentrations of 10, 30 and 34 µg/mL. Plasma calibration standards in the range of 25–10000 ng/mL were prepared from the 30 µg/mL working stock by serial dilution. Plasma lowest limit of quantification (LLOQ, 25 ng/mL), low quality control (LQC, 75 ng/mL) and medium quality control (MQC, 4500 ng/mL) samples were prepared from the 34 µg/mL working stock while the high quality control (HQC, 8500 ng/mL) samples was prepared from the 10 µg/mL working stock. A 5 µg/mL working stock of 13C-labeled efavirenz in plasma was prepared by spiking an appropriate volume of its intermediate stock (100 µg/mL in methanol-water (50:50, v/v) prepared from the 1 mg/mL stock) in plasma and used as internal standard.

Efavirenz CVS STDs and QCs samples were prepared by completely inserting each swab in the corresponding plasma STDs and QCs until full saturation. Each swab was transferred into 1.8 mL cryovials and stored at -80 °C until analysis.

Sample pre-treatment
Each swab was transferred into a 7 mL screw cap tube and extracted with 1 mL of methanol by tumbling for 30 min in the presence of 20 µL of IS. The tubes were centrifuged at 4000 rpm for 10 min and 500 µL of the extract was transferred into 5 mL glass tube and evaporated to dryness under a gentle stream of nitrogen gas. The residue was reconstituted in 500 µL of mobile phase A (50%) and B (50%). After centrifugation for 5 min at 4000 rpm, 250 µL was transferred into a new 5 mL glass tube and diluted with 250 µL of mobile phase. This was followed by further centrifugation at 4000 rpm for 5 min and 300 µL was transferred into autosampler vial for injection.

Calibration curves, accuracy and precision
Five separate validation assay batches were run, each consisting of a zero blank, ten calibrators in the range of 25–10000 ng/mL (n = 2 for each level), and QCs (n = 6 for each level). Calibration curves were constructed using a linear regression equation of analyte/IS peak area ratio versus nominal concentrations with a 1/concentration weighting. Percentage deviation of measured concentrations from nominal values was used to define accuracy and the percentage coefficient of variation (%CV) defined precision. In any batch, at least 75% of STDs and 67% of QCs (and at least 3 at each level) were required to have percentage deviation within ±15%, with an additional ±5% permitted for the lower limit of quantification (LLOQ)10.

Evaluation of room temperature drying and efavirenz stability in dried CVS
To assess the feasibility of room temperature drying, CVS samples collected from some of the participants in the VADICT study were used. To evaluate its clinical utility, the validated method was used to quantify efavirenz in intensive CVS pharmacokinetic samples collected from some of the participants in the VADICT study (ClinicalTrials.gov Identifier: NCT03284645) who received 600 mg efavirenz daily as part of antiretroviral therapy. The samples were also collected by inserting the swabs into the vagina until saturation, from six different healthy volunteers (n = 9 per volunteer) who had not taken any drug during the 2 weeks prior to sampling. The CVS samples were collected and stored in cryovials at -80°C. Each sample was brought to room temperature and extracted as described under sample pre-treatment. Matrix effect was calculated at LQC, MQC and HQC for each lot of matrix using the ratio of the peak area in the presence of matrix (measured by analysing blank matrix spiked with efavirenz after extraction), to the peak area in the absence of matrix (measured by analysing pure solution of the efavirenz in mobile phase).

Clinical application
To evaluate its clinical utility, the validated method was used to quantify efavirenz in intensive CVS pharmacokinetic samples collected from some of the participants in the VADICT study (ClinicalTrials.gov Identifier: NCT03284645) who received 600 mg efavirenz daily as part of antiretroviral therapy. The samples were also collected by inserting the swabs into the vagina until saturation. The VADICT study recruited patients between December 2017 and January 2019 at the Federal Medical Centre and the Bishop Murray Medical Centre, Makurdi, Benue State, Nigeria. The protocol and material transfer agreement (MTA) were approved by the National Health Research and Ethics Committee, Abuja, Nigeria (approval number: NHREC/01/01/2007-05/06/2017). Participation was voluntary and study details were clearly explained to potentially eligible patients in the language they understand (the local Tiv language, Nigerian Pidgin or English) before any study activity. Only participants who signed a written informed consent form were enrolled. A detailed description of the study protocol has been published elsewhere11.

CVS sample collection procedure
In brief, participants were required to refrain from unprotected sexual intercourse for at least 12 h before sample collection. Participants laid down for 5 min before each sample collection to allow pooling of fluid in the back of the vagina. To collect the CVS sample, the head of each FLOQSwab® was gently inserted approximately 3 inches into the vagina. While separating the labia with one hand, the other hand was used to hold the FLOQSwab® between the thumb and forefinger. The head of the FLOQSwab® was inserted further until it touched the back of the posterior fornix. The swab was gently rubbed...
against the mid-vaginal walls for at least 30 sec, withdrawn and immediately transferred into a cryovial. A total of 35 intensive CVS samples from five postpartum women were collected at 0.5, 1, 2, 4, 8, 12 and 24 h after an observed evening dose of a fixed-dose combination tablet containing 600 mg efavirenz. Paired DBS samples were collected at each time point on Whatman 903 protein saver cards following finger prick with a safety lancet. Samples were stored at -80 °C at the Federal Medical Centre, Makurdi, until transferred to the Translational Pharmacokinetics Research Laboratory, Obafemi Awolowo University, Ile-Ife using Arctic Express® Dry Shipper (Thermo Scientific, Waltham, MA, USA) where they were stored at -80 °C until analysis.

To demonstrate the feasibility of performing assay on CVS samples dried and stored at room temperature, some sparse CVS samples from 14 pregnant participants in the VADICT study collected using the same approach as above, were removed from the -80 °C freezer and left to dry at room temperature overnight at the Translational Pharmacokinetic Research Laboratory, Obafemi Awolowo University, Nigeria. They were transferred into new vials and individually packed in ziplock bags with desiccants along with paired DBS samples and posted at room temperature to the University of Liverpool for analysis.

Efavirenz in CVS was quantified using the newly developed and validated method while efavirenz in DBS was quantified using a previously described method and plasma concentrations were estimated using the equation: \[ \text{[DBS]}_{\text{Fav}}/(1-\text{HCT})\times 0.995, \]

where \[ \text{DBS}_{\text{Fav}} \] is efavirenz concentration in DBS, HCT is the patient-specific haematocrit and 0.995 is the fraction of efavirenz bound to plasma protein. Both the CVS and DBS methods were initially set up at the Bioanalytical Facility, University of Liverpool, UK and were later successfully transferred to the Obafemi Awolowo University Bioanalytical Laboratory, Ile-Ife, Nigeria where the TSQ Quantum Access liquid chromatography tandem mass spectrometry system is now located and the analysis of the intensive pharmacokinetic samples was implemented. The area under the concentration-time curve over a 24-h dosing interval (AUC\(_{0-24h}\)) was determined using the trapezoidal rule, the apparent clearance (Cl/F) was calculated by dividing dose by AUC\(_{0-24h}\) while the maximum (C\(_{\text{max}}\)), minimum concentration (C\(_{\text{min}}\)), and time to reach maximum concentration (T\(_{\text{max}}\)) were determined by visual inspection.

Liquid chromatography tandem mass spectrometry conditions

Representative chromatograms are presented in Figure 1 showing efavirenz at the LLOQ, LQC and a patient CVS. The total runtime was 7 min and the retention time was 2.8 min for both efavirenz and the IS, efavirenz-\(^{13}\)C6. The MS transitions were 314.042 → 242.083 and 244.087 m/z for efavirenz and 320.099 → 247.970 and 249.990 m/z for the IS with optimal collision energies of 21 and 20, 18 and 16, respectively.

Linearity, accuracy and precision

The method was linear with a weighting factor (1/\(x\)) in the range of 25–10000 ng/mL with inter- and intra-day precision (% CV) was between 7.69 and 14.9%, and accuracy (% bias) ranged from 99.1 to 105.3%. (Table 1). These values are within the acceptance criteria established \textit{a priori} as per FDA guidance. The mean regression coefficient (\(r^2\)) was > 0.99.

Room temperature drying and efavirenz stability in dried CVS

Drying for two hours resulted in a 12.9% weight loss at room temperature and 12.3% at 45 °C, with additional 0.03 and 0.04% respectively after 3 h. Constant weight was achieved after 8 h at room temperature and 5 h at 45 °C. Hence, drying at room temperature for 8 h or more was considered optimal. Efavirenz remained stable in CVS after drying at room temperature and storage at same for 24 h (LQC, 96.8%; MQC, 110%; HQC, 108%) and 35 days (LQC, 98.5%; MQC, 96.9%; HQC, 104%).

Efavirenz recovery from CVS and matrix effect

The pre-treatment method described above resulted in an average (SD) recovery of efavirenz from CVS of 83.8% (9.4) with %CV of 11.2; 74.1% at LQC, 84.4% at MQC and 92.9% at HQC. The overall matrix effect was 92.7% (5.8), 98.6% at LQC, 92.4% at MQC and 87.1% at HQC, with an overall % CV of 6.2.

Clinical application

A total of 98 samples (35 paired intensive CVS and DBS samples, 14 paired sparse CVS and DBS samples) from 19 participants were available for this analysis. The five postpartum women who contributed the intensive pharmacokinetic samples had a mean (SD) age of 29.3 years (7.3), weight was 70.2 kg (11.8), and they were at 46.2 weeks (6.2) postpartum. Duration on fixed dose combination of efavirenz with lamivudine and tenofovir was 4.5 years (1.9) and samples were collected at seven time points during a 24-hour dosing interval. The 14 pregnant women who participated in the sparse pharmacokinetic sampling were 31.5 years (5.9) old, weight was 74.4 kg (16.0), duration on fixed dose combination of efavirenz with lamivudine and tenofovir was 3.7 years (3.3), and samples were collected 14.2 hours (0.75) after the last dose and at 34.1 weeks (4.2) of gestation.

Based on the 35 CVS efavirenz concentration-time data contributed by 5 postpartum women, median (range) CVS efavirenz AUC\(_{0-24h}\) was 16370 ng*h/mL (5803–22088), C\(_{\text{max}}\) was 1618 ng/mL (610–2438) at a T\(_{\text{max}}\) of 8.0 h (8.0–12), and C\(_{\text{min}}\) was
Figure 1. Representative chromatograms showing efavirenz (and the internal standard, efavirenz-13C6) at the lower limit of quantification (LLOQ, 25 ng/mL), low quality control (LQC, 75 ng/mL), in a patient sample (1589 ng/mL).

399 ng/mL (110–981). The corresponding plasma (DBS-derived) AUC$_{0-24h}$ was 34772 ng*h/mL (25841–43987), C$_{max}$ was 4752 ng/mL (3602–5363) at a T$_{max}$ of 2.0 h (2.0–4.0), and C$_{min}$ was 1728 ng/mL (1127–2514). Efavirenz CVS:plasma AUC$_{0-24h}$ ratio was 0.41 (0.20–0.59). The combined and individual patient CVS and plasma concentration-time profiles are presented in Figure 2. Efavirenz C$_{min}$ in CVS was above the protein binding adjusted IC$_{95}$ of 126 ng/mL for wild-type HIV-1, but below the 470 ng/mL trough plasma effective concentration threshold established in the ENCORE 1 study in 74% of patients.
Efavirenz was successfully quantified in dried CVS samples \( (n = 14) \), the median (range) concentration was 1144 ng/mL (173-6379) and the corresponding plasma concentration (DBS derived) was 1619 ng/mL (891-7049). The CVS:plasma concentration ratio was 0.58 (0.13-1.4) for these paired samples collected at 14.2 hours (0.75) after the last dose. A positive correlation was observed between CVS and plasma efavirenz concentrations (Pearson \( r = 0.62; R^2 = 0.38 \)) in this limited number of paired sparse samples.

### Discussion

To facilitate intensive pharmacokinetic studies to better understand the pharmacology of therapeutics in the female genital tract, we developed and validated a simple, accurate and precise method for drug quantification in cervicovaginal fluid collected with flocked swab (using efavirenz as example). The utility of the new method was demonstrated in a small pharmacokinetic study of efavirenz in CVS samples from pregnant and postpartum HIV-infected women taking efavirenz-based antiretroviral therapy. Additionally, the feasibility of room temperature drying and storage was demonstrated, further extending its application to settings with limited ultra-low temperature storage facilities.

In this cohort of postpartum women, mean efavirenz CVS:plasma AUC\(_{\text{24h}}\) ratio was 0.41 (range: 0.20-0.59), individual patient profiles indicated substantial variability within the 24-hour dosing interval and between individuals. Importantly, efavirenz C\(_{\text{min}}\) in CVS was above the protein binding adjusted IC\(_{95}\) for wild-type HIV-1 of 126 ng/mL in all patients. This implies that the drug can optimally suppress viral replication in the FGT and reduce MTCT risks. The preparation of standards and QCs in the CVS method described in this paper closely mimics the procedure for specimen collection in patients. Importantly, this departs from previously reported methods in which specific volumes of spiked matrix were applied to swabs using pipette. The latter method requires obtaining the weight of each swab pre- and post-collection, otherwise the resulting calibration curves will underestimate drug concentration in patient samples. This new method effectively eliminates this requirement, significantly simplifies and is expected to improve pharmacokinetic studies in female genital tract.

To illustrate, the female genital tract constitutes a major route of heterosexual and mother-to-child transmission of HIV during delivery.Suppressive antiretroviral therapy reduces transmission risk. The development of precise and accurate bioanalytical method to accurately determine drug concentration in the female genital tract is important to understand antiretroviral distribution pattern in this compartment. For example, in HIV prevention trials among women, characterisation of drug distribution in this compartment for different delivery technologies will facilitate proper assessment of antiretroviral exposure-response relationships. This will enable the selection of the

### Table 1. Linearity, accuracy (%) and precision (%) for the quantification of efavirenz in cervicovaginal swab (CVS). SD=standard deviation.

| Nominal concentration (ng/mL) | Measured concentration (inter-day) |  | Measured concentration (intra-day) |  |
|-------------------------------|-----------------------------------|--------------------------|-----------------------------------|--------------------------|
|                               | mean | SD  | precision (%CV) | accuracy (%) | mean | SD  | precision (%CV) | accuracy (%) |
| 25                             | 25.7 | 1.31| 5.10           | 102.7        | 25.6 | 1.63| 6.36           | 102.3        |
| 50                             | 47.2 | 4.44| 9.40           | 94.5         | 48.0 | 5.32| 11.1           | 96.0         |
| 100                            | 91.9 | 6.61| 7.19           | 91.9         | 91.8 | 4.75| 5.18           | 91.8         |
| 200                            | 193  | 11.6| 6.00           | 96.4         | 195  | 17.3| 8.89           | 97.3         |
| 500                            | 498  | 41.9| 8.41           | 99.5         | 480  | 57.0| 11.9           | 96.0         |
| 1000                           | 1010 | 70.9| 7.00           | 101.4        | 1030 | 93.1| 8.99           | 103.5        |
| 2000                           | 2030 | 120 | 5.89           | 101.4        | 2005 | 112.3| 5.60           | 100.3        |
| 4000                           | 3990 | 208 | 5.22           | 99.8         | 4050 | 138.3| 3.41           | 101.3        |
| 7500                           | 7780 | 402 | 5.17           | 103.7        | 7940 | 457 | 5.75           | 105.9        |
| 10000                          | 10400| 768 | 7.39           | 104.0        | 10530| 1020| 9.68           | 105.3        |
| 25 (LLOQ)                      | 24.6 | 2.01| 8.14           | 98.5         | 24.2 | 1.86| 7.69           | 96.9         |
| 75 (LQC)                       | 75.0 | 6.33| 8.44           | 99.9         | 74.3 | 4.38| 5.90           | 99.1         |
| 4500 (MQC)                     | 4640 | 457 | 9.85           | 102.7        | 4740 | 496 | 10.5           | 105.3        |
| 8500 (HQC)                     | 8440 | 983 | 11.6           | 105.2        | 8470 | 1260| 14.9           | 99.6         |
Figure 2. Concentration-time profiles of efavirenz in cervicovaginal fluid collected with flocked swabs and plasma. The median (range) cervicovaginal swab (CVS) efavirenz AUC$_{0-24h}$ estimated from the pooled data (n = 5) was 16370 ng*h/mL (5803-22088), C$_{max}$ was 1618 ng/mL (610-2438) at a T$_{max}$ of 8.0 h (8.0-12), and C$_{min}$ was 399 ng/mL (110-981). Efavirenz CVS:plasma AUC$_{0-24h}$ ratio was 0.41 (0.20-0.59). Efavirenz C$_{min}$ in CVS was above the protein binding adjusted IC$_{95}$ for wild-type HIV-1 of 126 ng/mL (lower dashed lines) in all five patients and but below the 470 ng/mL (upper dashed lines) trough plasma effective concentration threshold established in the ENCORE 1 study in three out of five patients.
best in class technologies and therapeutics for optimal clinical benefits. An important consideration in this regard is the reliability of female genital fluid drug concentration as a surrogate for tissue concentration. Moderate to high correlations of cervicovaginal fluid with mucosal tissue concentration has been reported for four antiretrovirals ($r^2 = 0.37$ for maraviroc, 0.45 for tenofovir, 0.50 for emtricitabine and 0.74 for raltegravir; $P < 0.001$). Hence, for these drugs intensive pharmacokinetic data from the genital fluid could supplement sparse genital tissue data where quantitative assessment of drug concentration is needed. The method reported here will facilitate similar studies that aim to establish the relationship between efavirenz concentration in CVS and cervicovaginal tissue. With increasing interest in long-acting antiretroviral formulations, establishing target tissue concentration will ensure an evidence-based approach in selecting an optimal dose and dosing frequency. Although, efavirenz is currently not included in the approved PrEP plan, it is interesting to note that we have previously demonstrated its utility for PrEP repurposing using population pharmacokinetics-pharmacodynamic modelling.

CVS efavirenz concentrations in this study are more than the 18.4 ng/mL (6.95, 48.73) in 13 women at 8–12 h previously reported by Kwara et al. The CVS:plasma concentration ratio of 0.01 (0.00-0.03) obtained from the sparse pharmacokinetic data in the same study is significantly less than the CVS: plasma efavirenz AUC$_{0-24h}$ ratio of 0.41 (0.20-0.59) observed in the present study. An earlier study reported a ratio of 0.25 (0.06, 1.05) at 3–4 h and 0.08 (0.01, 0.53) at 8–12 h after dose. Both studies used directly aspirated genital fluid samples. Alternatively, flocked swabs were used for cervicovaginal fluid collection in this study and efavirenz was quantified using a method specifically validated for CVS. Hence, the use of different sampling techniques makes direct comparison across different studies difficult and impractical. Additionally, it is unclear if patients in previous studies were pregnant or non-pregnant women. Patients who contributed intensive pharmacokinetic samples in this study were postpartum women while those who contributed sparse samples were pregnant (34.1 weeks of gestation). The influence of changes in CVF volume associated with the menstrual cycle and pregnancy on drug concentration in the CVF require further investigation as the present study was not designed to address these.

Adequate penetration of tenofovir and lamivudine (taken in combination with efavirenz by patients in the present study) has been reported, with CVF:plasma concentration ratio of 3.2 (1.2-8.5) for lamivudine and 5.2 (1.2-22.6) for tenofovir in one study at 8–12 h after dosing. In that study, samples were collected at two time points and CVF:plasma concentration ratios at 3–4 h were less than at 8–12 h after dosing for all 13 antiretrovirals evaluated. An extensive review of the pharmacokinetics of antiretrovirals in the female genital tract was previously published, indicating the use of direct aspirate in most studies and a trend for class-specific differences: nucleoside reverse transcriptase inhibitors > nonnucleoside reverse transcriptase inhibitors > protease inhibitors. CVF:plasma concentration ratios of 0.06 for dolutegravir, and above 1.0 for rilpivirine have been reported. Population and physiologically based pharmacokinetic models of antiretrovirals in female genital tract have also been described. Complementary to these are recently described deterministic and quantitative structure activity relationship models of vaginal drug distribution describing sources of variability and potential application across different delivery systems and species. In addition to generating data to validate such models, the application of the new method reported here to other drug candidates could facilitate more clinical studies and accelerate progress towards the establishment of reliable exposure-response relationships for interventions aimed at preventing heterosexual and mother-to-child transmission of diseases across the vaginal mucosa.

The use of drug-free plasma in the preparation of calibration standards and QC samples instead of drug-free cervicovaginal fluid due to sample inaccessibility is one of the limitations of the present study. However, no significant matrix effect was observed. Some authors have reported diluting cervicovaginal fluid up to twenty times with water to obtain sufficient volume for assay development and validation. Another limitation is non-availability of cervicovaginal fluid aspirate or lavage from the same patients who contributed CVS for cross-validation with the CVS method. Though efavirenz is known to be stable in DBS at room temperature for at least 18 months, assessment of its stability in dried CVS over a longer period than the 35 days evaluated in this study is still desirable to further build confidence. Estimation of plasma concentrations from DBS concentrations is another limitation of this study. However, it has been established in previous studies that this estimation close to measured plasma concentrations. This method is now being used for the assay of sparse and intensive pharmacokinetic samples in the VADICT study. The associated standard operating procedure for the collection of CVS for pharmacokinetic and viral load assessments is available upon request.

Data availability
Underlying data
Open Science Framework. Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using LC-MS/MS (datasets). https://doi.org/10.17605/OSF.IO/698U3.

This project contains the following underlying data:
- Efavirenz in CVS_clinical PK dataset_210707.csv
- Efavirenz in DBS_clinical PK dataset_210707.csv
- Efavirenz in plasma_clinical PK dataset_210707.csv
- Efavirenz in dried CVS_plasma_sparse clinical PK dataset.csv
- Flocked swabs weight uniformity tests_210908_2.csv
- Interday precision and accuracy_210908.csv
- Intraday precision and accuracy_210908.csv
Matrix effect experiment_210908.csv
Patients demographic data210908.csv
Recovery experiment_210908.csv
Stability after drying at RT experiment_35days_210908.csv

Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).

References

1. Baeten JM, Kahle H, Lingappa JR, et al: Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med. 2011; 3(77): 77ra29. PubMed Abstract | Publisher Full Text | Free Full Text
2. John GC, Nakuru RW, Mbita-Ng'echa DA, et al: Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis. 2001; 183(2): 206–12. PubMed Abstract | Publisher Full Text
3. Taylor S, Boffito M, Vernazza PL: Efavirenz, emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. J HIV Ther. 2003; 8(S1): A38–A39. PubMed Abstract | Publisher Full Text | Free Full Text
4. Patterson KB, Prince HA, Kraft E, et al: Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011; 3(12): 112re4. PubMed Abstract | Publisher Full Text | Free Full Text
5. Olagunju A, Balaji OQ, Amara A, et al: Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. J Antimicrob Chemother. 2015; 70(2): 555–61. PubMed Abstract | Publisher Full Text | Free Full Text
6. Cottrell ML, Prince HM, Allmon A, et al: Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design. J Acquir Immune Defic Syndr. 2016; 72(3): 498–506. PubMed Abstract | Publisher Full Text | Free Full Text
7. Bennett-Hood C, Johnson VA, King JR, et al: Novel methodology for antiretroviral quantitation in the female genital tract. HIV Clin Trials. 2009; 10(3): 193–9. PubMed Abstract | Publisher Full Text | Free Full Text
8. Amara AB, Else LJ, Tjia J, et al: A validated method for quantification of efavirenz in dried blood spots using high-performance liquid chromatography-mass spectrometry. Ther Drug Monit. 2015; 37(2): 220-8. PubMed Abstract | Publisher Full Text
9. Olagunju A, Akenso D, Okafor O, et al: Viral and antiretroviral dynamics in HIV mother-to-child transmission fluids (VADICT) – Protocol and data analysis plan for a cohort study [version 1; peer review: 1 approved with reservations]. Wellcome Open Res. 2019; 4(34): 34. Publisher Full Text
10. Food and Drug Administration (FDA): Guidance for Industry. Bioanalytical Method Validation. Maryland: Food and Drug Administration, US Department of Health and Human Services, 2018. Reference Source
11. Olagunju A, Awosile D, Okafor O, et al: Viral and antiretroviral dynamics in HIV mother-to-child transmission fluids (VADICT) – Protocol and data analysis plan for a cohort study [version 1; peer review: 1 approved with reservations]. Wellcome Open Res. 2019; 4(34): 34. Publisher Full Text
12. Accota EP, Linsol KL, Trinh L, et al: Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. Antimicrob Agents Chemother. 2012; 56(11): 5938–45. PubMed Abstract | Publisher Full Text | Free Full Text
13. Dickinson L, Amin J, Else L, et al: Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study. Clin Pharmacokinet. 2016; 55(7): 861–873. PubMed Abstract | Publisher Full Text | Free Full Text
14. Duval S, Seeler D, Dickinson L, et al: The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis. Front Pharmacol. 2019; 10: 199. PubMed Abstract | Publisher Full Text | Free Full Text
15. Duval S, Dickinson L, Zhou S, et al: Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis. PLoS Comput Biol. 2019; 15(1): e1007640. PubMed Abstract | Publisher Full Text | Free Full Text
16. Kwara A, Delong A, Rezk N, et al: Antibody response to antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008; 46(3): 719–25. PubMed Abstract | Publisher Full Text | Free Full Text
17. Mis S, Corbett AH, Rezk N, et al: Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women. J Acquir Immune Defic Syndr. 2004; 37(3): 1577–80. PubMed Abstract | Publisher Full Text | Free Full Text
18. Usula SJ, Schumacher GF: Volumetric self-sampling of cervicovaginal fluid: a new approach to ovulation timing. Fertil Steril. 1983; 39(3): 304–9. PubMed Abstract | Publisher Full Text | Free Full Text
19. Dumond JB, Nicol MR, Kendrick RN, et al: Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women. Clin Pharmacokinet. 2012; 51(12): 809–22. PubMed Abstract | Publisher Full Text | Free Full Text
20. Else LJ, Taylor S, Back D, et al: Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011; 16(8): 1149–67. PubMed Abstract | Publisher Full Text | Free Full Text
21. Adams JL, Patterson KB, Prince HM, et al: Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women. Antivir Ther. 2013; 18(8): 1005–13. PubMed Abstract | Publisher Full Text | Free Full Text
22. Lé MP, Belarbi L, Chaix ML, et al: Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both male and female genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals. J Antimicrob Chemother. 2017; 72(11): 3167–71. PubMed Abstract | Publisher Full Text | Free Full Text
23. Van Niekerk N, Nuttall J, Zeiser S, et al: Volumetric self-sampling of cervicovaginal secretions from ophthalmic tear strips and polymer-based swabs via liquid chromatographic-tandem mass spectrometry (LC-MS/MS) analysis. J Pharm Biomed Anal. 2014; 89: 407–16. PubMed Abstract | Publisher Full Text | Free Full Text
24. Parsons TL, Emory JF, Sereko LA, et al: Dual quantification of dapivirine and maraviroc in cervicovaginal secretions from ophthalmic tear strips and polymer-based swabs via liquid chromatographic-tandem mass spectrometry. J Pharm Biomed Anal. 2014; 89: 407–16. PubMed Abstract | Publisher Full Text | Free Full Text

Acknowledgements

We acknowledge infrastructural support from the Liverpool Biomedical Research Centre funded by Liverpool Health Partners and appreciate the support of the staff. We would also like to thank the participating patients, staff and management of Federal Medical Centre, Makurdi, Nigeria for their ongoing support of the VADICT study. Fogarty International Center of the National Institutes of Health provided research training support for Jacinta Nwogo under award number D43TW009608.
Open Peer Review

Current Peer Review Status:  

**Version 3**

Reviewer Report 15 August 2022

https://doi.org/10.21956/wellcomeopenres.19999.r51456

© 2022 Choong E. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

✅ Eva Choong

Service and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland

Thank you for the amendments

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** analytical chemistry, TDM, clinical pharmacology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

---

**Version 2**

Reviewer Report 28 April 2022

https://doi.org/10.21956/wellcomeopenres.19759.r49810

© 2022 Choong E. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

❓ Eva Choong

Service and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland

The authors revised the manuscript and answered most of the points raised in the review. However, the two points below must still be revised before acceptance.
Former Point 13 of the review was not satisfactorily fulfilled (below in italic). The answer of the authors could be scientifically questioned. Please, modify the manuscript accordingly, and, please, add this point in the limitations of the study:

Review: As no comparison between efavirenz tissue and CVS levels were reported (and only a few for four antiretroviral drugs are described in the literature) the authors should emphasize the results that lead them to the general statement “Hence, intensive pharmacokinetic data from the genital fluid could supplement sparse genital tissue data where the quantitative assessment of drug concentration is needed. Hence, the method reported here will facilitate studies that aim to establish pharmacokinetic targets (…)”.

Authors’ answer nº13 “The authors consider the data reported earlier on the relationship of efavirenz tissue and CVS for four antiretroviral drugs reliable until other data can prove otherwise. Therefore, the statement is suggestive and general”

Former point 14 regarding efavirenz as a future PrEP agent: The two references related to this point are from some of the co-authors of the present manuscript. For clarity for the reader, please modify it as “it is interesting to note that we have recently demonstrated its utility for PrEP repurposing using population....”

Authors’ answer pt 14: The statement has been rephrased to “Although, efavirenz is currently not included in the approved PrEP plan, it is interesting to note that its utility for PrEP repurposing was recently demonstrated using population....”

Minor modifications:

Former point 5: could you confirm that it is written in the limitations, please?

Authors’ answer to point 5: The quantification of efavirenz in the 14 sparse samples was demonstrated to evaluate the stability of the drug in the matrix after subjecting them to a drying process, similar to that obtainable in clinical procedures in resource limited areas lacking low temperature storage conditions. A more robust stability study of the drug in CVS is desirable.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: analytical chemistry, TDM, clinical pharmacology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 07 Jul 2022

Adeniyi Olagunju, University of Liverpool, Liverpool, UK

Thank you for highlighting these points. We have now addressed them in the version 3 of the manuscript as indicated below.
Reviewer comment: Former Point 13 of the review was not satisfactorily fulfilled (below in italic). The answer of the authors could be scientifically questioned. Please, modify the manuscript accordingly, and, please, add this point in the limitations of the study.

Revision: The statement under limitations has now been edited as follows: “The method reported here will facilitate similar studies that aim to establish the relationship between efavirenz concentration in CVS and cervicovaginal tissue”.

Reviewer comment: Former point 14 regarding efavirenz as a future PrEP agent: The two references related to this point are from some of the co-authors of the present manuscript. For clarity for the reader, please modify it as “it is interesting to note that we have recently demonstrated its utility for PrEP repurposing using population....”

Revision: “Although, efavirenz is currently not included in the approved PrEP plan, it is interesting to note that we have previously demonstrated its utility for PrEP repurposing using population pharmacokinetics-pharmacodynamic modelling”.

Reviewer comment: Former point 5: could you confirm that it is written in the limitations, please?

Revision: Yes, this was included under limitations in the last paragraph under discussion in version 2: “Though efavirenz is known to be stable in DBS at room temperature for at least 18 months, assessment of its stability in dried CVS over a longer period than the 35 days evaluated in this study is still desirable to further build confidence”.

Competing Interests: No competing interests were disclosed.
developed in a logical and clear way.

Certainly, the work has some aspects of certain originality inside it while the rest is of normal routine even if of a good scientific and technological level.

The results that the authors report in this work are significant and interesting, and for this and other reasons mentioned above, I believe that the manuscript after a slight correction of the English language can be seriously considered for indexing.

Is the rationale for developing the new method (or application) clearly explained?
Yes

Is the description of the method technically sound?
Yes

Are sufficient details provided to allow replication of the method development and its use by others?
Yes

If any results are presented, are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions about the method and its performance adequately supported by the findings presented in the article?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Analytical Chemistry; LC/MS; GC/MS

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
The study describes an analytical method development in LC-MS/MS to quantify the antiretroviral efavirenz from DBS and swab. The method is then used for efavirenz pharmacokinetics analysis in HIV pregnant and post-partum women (n=19) for paired DBS and cervicovaginal (CVS) samples. The manuscript is well written. Information on efavirenz levels in different compartments, including in female genital tract and its penetration to this compartment is pharmacologically highly relevant. The authors use CVS as a surrogate of the genital tract tissue and a calculated plasma level from DBS samples to characterize CVS: plasma ratios.

Yet, some confusion on the studied matrix (blood/plasma vs. cervicovaginal sample) appeared along with the manuscript, no assessment of the accuracy of the method in cervicovaginal matrix are performed, nor a comparison for DBS versus plasma levels. Moreover, the “CVS” term tends to be used indefinite to describe the flocked swab (the tool) and the cervicovaginal matrix (for instance in: “Efavirenz CVS STDs and QCs samples were prepared by completely inserting each swab in the corresponding plasma STDs and QCs until full saturation”). Finally, the plasma levels are estimated with a formula and should be specified in the whole manuscript accordingly (i.e. plasma_{estimated} level). Moreover, this estimation is calculated with a fixed percentage of efavirenz protein bound. Yet, the manufacturer reported already an interval (99.5-99.75% protein bound, see EPAR) and this percentage should be used with even more cautious during pregnancy patients for whom drugs free/unbound fraction can much vary.

**Major modifications:**

- The authors should better explain for each experiment 1. which matrices were taken and 2. differentiated flocked swab (the tool) and the cervicovaginal matrix.

- In this context, the authors should also modify:
  - In methods and results, the titles as such
    - Plasma swab saturation and weight uniformity
    - Plasma preparation of stock solutions, calibration standards (STD) and quality controls (QC) samples
    - Room temperature drying and efavirenz stability in dried CVS plasma
  - Modify the term matrix by specifying either plasma or cervicovaginal fluid

- A comparison of patients’ efavirenz levels in DBS vs plasma should be performed.

- An assessment of the accuracy of the method in cervicovaginal matrix should be performed and confirmation of the adequacy to use plasma calibration instead of cervicovaginal calibration should be studied.

- The quantification of the 14 sparse samples (VADICT study) between direct analyses or after being left to dry was not assessed. The authors presents here only results after drying. Therefore, the process of drying in term of accuracy should be tested and efavirenz stability in this drying procedure should be studied.

- The authors should specify how they estimate the plasma level for dried CVS and how they take into account the DBS weight loss.

- The authors should ensure that the analytical method separates the N-glucuronide efavirenz metabolite from the parent drug as a co-elution could overestimate the actual
efavirenz level (i.e. the glucuronide of the metabolite can be cleaved during the MS evaporation process leading to detect the same m/z transition than the parent drug).

- The authors should specify how they extract the DBS (size of the spot if fixed diameter vs. the whole spot, reference of the DBS card manufacturer, etc).

- The authors should specify that it is an estimation of the plasma level and discuss this limitation.

- The authors should deeper discuss the potential clinical impact of efavirenz Cmin in cervicovaginal matrix as compared to the adjusted IC95 of 126ng/ml which is actually reported for plasma.

- The authors should explain what is the dosing interval in the following sentence as they stated that the patients take efavirenz 600mg QD “(...)individual patient profiles indicated substantial variability within the dosing interval and between individuals”.

- The authors should emphasized the results that lead them to the statement “This new method effectively eliminates this requirement (of weighting the swab), significantly simplifies and is expected to improve pharmacokinetic studies in female genital tract”, especially in regards to the limitation of the potential CVS volume change during pregnancy and menstrual cycle.

- As no comparison between efavirenz tissue and CVS levels were reported, and only a few for four antiretroviral drugs are described in the literature, the authors should emphasized the results that lead them to the general statement “Hence, intensive pharmacokinetic data from the genital fluid could supplement sparse genital tissue data where quantitative assessment of drug concentration is needed. Hence, the method reported here will facilitate studies that aim to establish pharmacokinetic targets (…)”.

- The two references for efavirenz as PrEP drug are from some of the co-authors and should be reported as such. In addition, it should be stated that efavirenz is not, at present, part of any recommended PrEP panel.

**Minor modifications:**

- Please, homogenize along the manuscript and legend AUC0-24h as the “h” is sometimes missing.

- Figure 2 C-F, please correct the y-axis (i.e. delete “in CVS” as plasma is also shown).

- Please delete subjective adjectives which are not scientifically defined:
  - Abstract -> delete INTENSIVE in “35 paired intensive CVS and DBS samples”
  - Result-> delete GOOD in “a good correlation was observed”

- Please add $R^2$ in “Pearson r=0.62; $R^2$ =0.38”.

- Please specify the percentage of mobile phase A in Sample pre-treatment “The residue was reconstituted in 500 µL of mobile phase A and B”.

---
Please indicate if the tenofovir used is TDF and/or if it is Atripla® as EACS Guidelines and others do not recommend TAF in pregnant women.

The relevance of the old generation efavirenz as an example for swab collection might be limited, its utility (cost, generic medicine) should be thus emphasized.

Please indicate in Methods / results the experiment that the authors referred in the discussion to “Another limitation is non-availability of cervicovaginal fluid aspirate or lavage from the same patients who contributed CVS for cross-validation with the CVS method”.

“The use of drug-free plasma in the preparation of calibration standards and QC samples instead of drug-free cervicovaginal fluid due to sample inaccessibility is one of the limitations of the present study. However, no significant matrix effect was observed. » The last sentence should be deleted as no experiment on this subject was performed.

Is the rationale for developing the new method (or application) clearly explained?
Yes

Is the description of the method technically sound?
Partly

Are sufficient details provided to allow replication of the method development and its use by others?
Partly

If any results are presented, are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions about the method and its performance adequately supported by the findings presented in the article?
Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: analytical chemistry, TDM, clinical pharmacology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 04 Apr 2022

Adeniyi Olagunju, University of Liverpool, Liverpool, UK

Thank you for your comments. Below are our responses in the order of the comments.
Responses to major comments
1. Thank you for your comment. The method has included a better indication of the matrices used.
2. The detailed descriptions of the matrices and how they were prepared or collected in different sections of the manuscript have been provided.
3. The relationship between DBS efavirenz and plasma concentrations has been previously performed and established in an earlier reported method (Alieu et al, 2015). Additionally, the calculated plasma concentrations from DBS were found to be very close to the actual measured plasma concentrations (Alieu et al, 2017). However, estimation of plasma concentration from DBS concentrations has been added as a limitation to the study.
4. Thank you for this comment. Inaccessibility of drug-free cervicovaginal fluid prevented the authors from using the matrix directly to evaluate the accuracy and other method development and validation parameters. And this was mentioned as part of the limitations of the study. In addition, the adequacy of using plasma instead of cervicovaginal fluids was studied and we found out that the use of plasma matrix does not affect the accuracy of our CVS method.
5. The quantification of efavirenz in the 14 sparse samples was demonstrated to evaluate the stability of the drug in the matrix after subjecting them to a drying process, similar to that obtainable in clinical procedures in resource limited areas lacking low temperature storage conditions. A more robust stability study of the drug in CVS is desirable.
6. All CVS QCs samples for stability were prepared as described (that is, efavirenz spiked plasma concentrations for the QCs were prepared and swabs inserted into the plasma samples were dried at the described temperature condition and durations). The swabs were then processed as described under sample pre-treatment and analysed accordingly.
7. The contribution of efavirenz N-glucuronidation to efavirenz elimination in vivo was characterized in the study by Cho et al (Antimicrob Agents Chemother. 2011 Apr;55(4):1504-9). Their findings indicated that while the “occurrence of direct efavirenz N-glucuronidation is supported by the urine data, the abundance of efavirenz N-glucuronide in plasma is negligible and that the contribution of the N-glucuronidation pathway to the overall clearance of efavirenz seems minimal”. We agree with this and believe any potential interference from this metabolite will be negligible.
8. The DBS samples were quantified using a previously reported method (Amara et al 2015).
   1. The DBS was quantified using a previously reported method (Amara et al 2015). Three 6 mm punches were extracted.
   2. Details of the DBS card used have been added under the sub-section “Material” in the body of the manuscript.
9. We have now included the following statement in the paragraph where we highlight other limitations: “Estimation of plasma concentration from DBS concentration is another limitation of this study. However, it has been established in previous studies that this estimation is close to measured plasma concentrations”.
10. This has been addressed in the second paragraph of the discussion.
11. Thank you. For clarity, the statement has been changed to “individual patient profiles indicated substantial variability within the 24-h dosing interval and between individuals.

12. Thank you for your comment. The authors were able to establish the volume of plasma absorbable by the flocked swabs used in this study (128µl). This guarantees consistency in sampling and eliminates the need to weigh the swab before and after sample collection (a major limitation of many of the previously described methods)
   1. While it is true that CVF volume may differ during pregnancy and menstrual cycles, the volume of CVF that can be collected with CVS will remain constant (provided the collection procedure is adhered to).

13. The authors consider the data reported earlier on the relationship of efavirenz tissue and CVS for four antiretroviral drugs reliable until other data can prove otherwise. Therefore, the statement is suggestive and general.

14. The statement has been rephrased to “Although, efavirenz is currently not included in the approved PrEP plan, it is interesting to note that its utility for PrEP repurposing was recently demonstrated using population....”

Responses to minor comments
   1. This has been attended to.
   2. Thanks for pointing this out. We have now corrected the axes labels.
   3. The authors have added a description of the intensive by adding pharmacokinetics to it. Hence, the statement is changed to “35 paired intensive CVS and DBS pharmacokinetic samples”.

Thank you. The word “good” has been replaced with “positive”.
   1. This has been added. Thank you.
   2. 50% each of mobile phases A and B.
   3. The patients that participated in this study were placed on TDF/3TC/EFV regiment.
   4. We included the following statement under the discussion section to highlight the need to evaluate the potential utility of this method for newer antiretroviral drugs:

“...In addition to generating data to validate such models, the application of the new method reported here to other drug candidates could facilitate more clinical studies and accelerate progress towards the establishment of reliable exposure-response relationships for interventions aimed at preventing heterosexual and mother-to-child transmission of diseases across the vaginal mucosa”.
   1. The authors were only trying to highlight the non-availability of CVF for use as a calibration matrix as one of the limitations of the CVS method developed in this study. No previously reported method or result was referred to in the quoted statement.
   2. The “matrix” here refers to the Swab. Hence the statement is rephrased to “However, no significant matrix effect from the swab was observed”.

**Competing Interests:** No competing interests were disclosed.